Ixekizumab is a monoclonal antibody used to treat moderate to severe plaque psoriasis. Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor.
- Mechanism
- Curator reviewed
Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflammatory conditions. In particular, IL-17A has been found to be implicated in a variety of autoimmune diseases including Rheumatoid Arthritis and plaque psoriasis.
- Primary indication
- Ixekizumab is indicated for the treatment of patients aged six years or older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.Curator reviewed · 4 structured indications
- Formula / weight
- C6492H10012N1728O2028S46 · 146158.0 Da
- First approval
- Canada, 2022 · United States, 2016 · European Union, 2016
- Code names
- LY-2439821
- Brand names
Resolves to
What you can answer from here — as of July 16, 2025
Which drugs share a target with Ixekizumab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account